SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-23-002764
Filing Date
2023-01-27
Accepted
2023-01-27 16:10:38
Documents
14
Period of Report
2022-12-12
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 46425
2 ex99-6.htm EX-99.6 245215
  Complete submission text file 0001493152-23-002764.txt   534719

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE zvsa-20221212.xsd EX-101.SCH 3462
4 XBRL DEFINITION FILE zvsa-20221212_def.xml EX-101.DEF 26188
5 XBRL LABEL FILE zvsa-20221212_lab.xml EX-101.LAB 35952
6 XBRL PRESENTATION FILE zvsa-20221212_pre.xml EX-101.PRE 24846
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 5260
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41184 | Film No.: 23562912
SIC: 2834 Pharmaceutical Preparations